MAPT and Alzheimer disease: Dauricine has the pharmacological activity of inhibiting APP processing, reducing Aβ accumulation, attenuating the hyperphosphorylation of tau (Liu et al., 2018), anti-oxidative and anti-apoptosis, and shows the potential therapeutic value for AD (Wang et al., 2020).